Newbury Park, CA, United States of America

Xiaolan Zhou

This inventor holds 27 USPTO granted patents and 14 published patent applications and 12 EPO patents, primarily in Biopharmaceutical Innovation. Top assignees: Amgen Inc., Atara Biotherapeutics, Inc., Alivegen Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaolan Zhou. Retrieved from https://idiyas.com/inventor/xiaolan-zhou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 14)

% Patents Active = 88.9

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 3.5

ph-index = 11

Forward Citations = 397(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2013 - 2019)
Newbury Park, CA (US) (2011 - 2024)

Company Filing History:

Atara Biotherapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Anti-Activin Antibodies

Hybrid ActRIIB Ligand

Tumor Necrosis Factor Alpha

Transforming Growth Factor Beta

Pulmonary Fibrosis

Bone Disease

Muscle Wasting

Dual Receptor Antagonists

Variant Activin Receptor

Nucleic Acid Molecules

Fusion Proteins

Antigen-Binding Proteins

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735508 - BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR ALPHA AND TRANSFORMING GROWTH FACTOR BETA AND METHOD OF USE THEREOF TO TREAT PULMONARY FIBROSIS AND PULMONARY ARTERIAL HYPERTENSION (2026-09-15),

2. 12703742 - BIFUNCTIONAL ANTAGONISTS OF ACTIVIN AND TUMOR NECROSIS FACTOR ALPHA AND USES THEREOF (2026-08-11),

3. 12383572 - Administration of an anti-activin-a compound to a subject (2025-08-12),

4. 12187783 - Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins (2025-01-07),

5. 11932677 - Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases (2024-03-19),

6. 11542325 - Anti-activin A antibodies and uses thereof (2023-01-03),

7. 11541070 - Administration of an anti-activin-A compound to a subject (2023-01-03),

8. 11292826 - Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases (2022-04-05),

9. 10981999 - Dual receptor antagonistic antigen-binding proteins and uses thereof (2021-04-20),

10. 10913782 - Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases (2021-02-09),

11. 10407487 - Variant activin receptor (2019-09-10),

12. 10266598 - Dual receptor antagonistic antigen-binding proteins and uses thereof (2019-04-23),

13. 10100109 - Anti-activin A antibodies and uses thereof (2018-10-16),

14. 9809638 - Variant activin receptor (2017-11-07),

15. 9610327 - Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof (2017-04-04),

Title: **Xiaolan Zhou: Innovating Therapies for Muscle Wasting and Bone Diseases**

Introduction

Xiaolan Zhou, based in Newbury Park, CA, is a prolific inventor with a remarkable portfolio that boasts 24 patents. His innovations primarily focus on advancements in therapies for muscle wasting and bone diseases, which could significantly enhance the quality of life for countless individuals suffering from these conditions.

Latest Patents

Zhou's latest patents include groundbreaking methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins. These innovations describe unique hybrid soluble ActRIIB-ECD polypeptides that maintain binding affinity for myostatin and activin A while demonstrating significantly reduced binding to BMPs, particularly BMP-9. The compositions detailed in these patents have the potential to modulate the growth of various tissues including muscle, bone, cartilage, fat, fibroblasts, blood, and neuronal tissues. This modulation can counteract issues such as muscle wasting, bone loss, anemia, inflammation, and fibrosis effectively. By offering safer and more effective alternatives to current myostatin inhibitors, these next-generation therapies are poised to be beneficial across a wide range of clinical applications.

Career Highlights

Throughout his career, Xiaolan Zhou has made significant contributions while working with prestigious companies such as Amgen Inc. and Atara Biotherapeutics, Inc. His expertise has facilitated the development of innovative therapeutic solutions that address critical health concerns.

Collaborations

Zhou has collaborated with other talented professionals in the field, including Keith Soo-Nyung Kwak and Huiquan Han. Together, they have worked on pioneering projects that advance therapeutic techniques and contribute to improved patient outcomes in the realm of muscle and bone health.

Conclusion

Xiaolan Zhou’s contributions through his patents stand as a testament to his commitment to innovation in medical science. His work in developing novel therapies for muscle wasting and bone diseases not only showcases his ingenuity as an inventor but also reflects the profound impact that dedicated researchers can have on healthcare advancements. As the field evolves, the implications of Zhou’s work will likely resonate, inspiring new solutions for ongoing medical challenges.

Profile summary based on public USPTO records.